Citi on Prime Medicine (PRME) with shares down 20pct: 'Initial Human Data from a Prime Editing Therapy Show Promise, but Financing Risk Remains a Key Overhang'
Tweet Send to a Friend
Citi analyst Samantha Semenkow reiterated a Buy rating and $10.00 price target on Prime Medicine (NASDAQ: PRME).The analyst comments "Prime ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
